Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Synlogic discontinues development of SYNB-1020 for the treatment of hyperammonemia

Aug. 21, 2019

Oral HRI activator EPB-53 improves glucose intolerance through FGF21

Aug. 21, 2019

ActoBio Therapeutics announces IND approval for AG-017 for the treatment of celiac disease

Aug. 21, 2019

Forendo Pharma initiates dosing in phase Ib study of FOR-6219

Aug. 20, 2019

SU-011 improves glycemic control in vivo without the risk of hypoglycemia and weight gain

Aug. 20, 2019

TRPV1 as a novel therapeutic target in type 2 diabetes mellitus

Aug. 19, 2019

Sunshine Lake Pharma discovers sodium/glucose cotransporter 1 inhibitors

Aug. 16, 2019

Positive topline results presented from ELIPSE HoFH phase III study of evinacumab

Aug. 16, 2019

Xiangbei Welman Pharmaceutical describes compounds for gout, hyperuricemia

Aug. 13, 2019

PCOS linked to interleukin-22 by way of microbiome

Aug. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...